Queen’s University Belfast has joined a UK-wide research programme into bowel cancer survival rates and how to tailor treatments to the patient’s specific genetic makeup.
Announced on 14 April, the S-CORT Consortium involves profiling more than 2,000 patients from large clinical trials and developing personalised treatment plans.
Nearly €7 million in funding comes from the Medical Research Council and Cancer Research UK. The project involves a collection of universities, drug companies and research charities and is led by Tim Maughan based at The University of Oxford.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.